ArticleJournal of gastroenterology2017
A human gut ecosystem protects against C. difficile disease by targeting TcdA.
Article in Journal of gastroenterology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 27 citations in OpenAlex.
- Article
- Deciphering gut microbiome patterns from host preferences and microbial interactions in healthy Korean individuals.BMC biology · 2025Article
- Defined microbial communities and their soluble products protect mice from Clostridioides difficile infection.Communications biology · 2024Article
- Synthetic microbial communities (SynComs) of the human gut: design, assembly, and applications.FEMS microbiology reviews · 2023Article
- Organoid-based Models to Study the Role of Host-microbiota Interactions in IBD.Journal of Crohn's & colitis · 2021Review
- Broad-Spectrum Inhibitor of Bacterial Polyphosphate Homeostasis Attenuates Virulence Factors and Helps Reveal Novel Physiology ofFrontiers in microbiology · 2021Article
- Gut microbiota-specific IgAScience immunology · 2020Observational
- Efficient inter-species conjugative transfer of a CRISPR nuclease for targeted bacterial killing.Nature communications · 2019Article
- The Use of Defined Microbial Communities To Model Host-Microbe Interactions in the Human Gut.Microbiology and molecular biology reviews : MMBR · 2019Review
- Effects of defined gut microbial ecosystem components on virulence determinants of Clostridioides difficile.Scientific reports · 2019Article
- Consortium of Probiotics Attenuates Colonization ofFrontiers in microbiology · 2019Article
- Microbiota transplantation: concept, methodology and strategy for its modernization.Protein & cell · 2018Review
- Treatment of recurrentGastroenterology report · 2018Review
- Control ofMicrobiology spectrum · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 6 institutions in 2 countries.
Funding
Abstract
backgroundA defined Microbial Ecosystem Therapeutic (MET-1, or "RePOOPulate") derived from the feces of a healthy volunteer can cure recurrent C. difficile infection (rCDI) in humans. The mechanisms of action whereby healthy microbiota protect against rCDI remain unclear. Since C. difficile toxins are largely responsible for the disease pathology of CDI, we hypothesized that MET-1 exerts its protective effects by inhibiting the effects of these toxins on the host.
methodsA combination of in vivo (antibiotic-associated mouse model of C. difficile colitis, mouse ileal loop model) and in vitro models (FITC-phalloidin staining, F actin Western blots and apoptosis assay in Caco2 cells, transepithelial electrical resistance measurements in T84 cells) were employed.
resultsMET-1 decreased both local and systemic inflammation in infection and decreased both the cytotoxicity and the amount of TcdA detected in stool, without an effect on C. difficile viability. MET-1 protected against TcdA-mediated damage in a murine ileal loop model. MET-1 protected the integrity of the cytoskeleton in cells treated with purified TcdA, as indicated by FITC-phalloidin staining, F:G actin assays and preservation of transepithelial electrical resistance. Finally, co-incubation of MET-1 with purified TcdA resulted in decreased detectable TcdA by Western blot analysis.
conclusionsMET-1 intestinal microbiota confers protection against C. difficile and decreases C. difficile-mediated inflammation through its protective effects against C. difficile toxins, including enhancement of host barrier function and degradation of TcdA. The effect of MET-1 on C. difficile viability seems to offer little, if any, contribution to its protective effects on the host.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.